Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vistagen Therapeutics, Inc.VTGN · Entity 7955 | Director · President and CEO | June 30, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vistagen Therapeutics, Inc.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,846 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 36,818 · Balance 54,846 F1: Represents acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended (the "ESPP"), in a transaction exempt under Rule 16b-3 and Rule 16b-3(d). The Reporting Person purchased the maximum amount permitted under the ESPP. |
| Common StockSEC Table I · non-derivative | IndirectBy The 1997 Singh Family Trust | 20,875 |
Reported balance
Holding disclosure · report date 2026-06-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20,875 F2: Shares held by The 1997 Singh Family Trust U/R/D 05/29/1997. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended (the "ESPP"), in a transaction exempt under Rule 16b-3 and Rule 16b-3(d). The Reporting Person purchased the maximum amount permitted under the ESPP.
F2: Shares held by The 1997 Singh Family Trust U/R/D 05/29/1997.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 2, 2026 20:16 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 36,818 | $0.19 | $7,072.74 |
DisclosureSEC source: 0001412071-26-000006 · form4-07022026_080729.xml · nonDerivative · entry 1 Singh Shawn · CIK 0001412071 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,846 F1 · kind: Represents acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended (the "ESPP"), in a transaction exempt under Rule 16b-3 and Rule 16b-3(d). The Reporting Person purchased the maximum amount permitted under the ESPP. Read SEC document |
| April 07, 2026 Filed Apr 10, 2026 00:41 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 71,268 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001412071-26-000004 · edgardoc.xml · derivative · entry 2 Singh Shawn · CIK 0001412071 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,268 Underlying: Common Stock · 71,268 shares Expires 2036-04-07 F1 · derivative.exercise_date: Represents stock options (the "Options") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. 25% of the Options will vest on the six-month anniversary of April 7, 2026 (the "Grant Date"), and will vest in 25% installments every six months thereafter until the Options become fully vested on the two (2) year anniversary of the Grant Date. Read SEC document |
| April 07, 2026 Filed Apr 10, 2026 00:41 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantIncentive Stock Option (right to buy) · Derivative | 3,732 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001412071-26-000004 · edgardoc.xml · derivative · entry 1 Singh Shawn · CIK 0001412071 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,732 Underlying: Common Stock · 3,732 shares Expires 2036-04-07 F1 · derivative.exercise_date: Represents stock options (the "Options") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. 25% of the Options will vest on the six-month anniversary of April 7, 2026 (the "Grant Date"), and will vest in 25% installments every six months thereafter until the Options become fully vested on the two (2) year anniversary of the Grant Date. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 21:48 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 7,541 | $1.70 | $12,819.70 |
DisclosureSEC source: 0001415889-25-018748 · form4-07012025_090724.xml · nonDerivative · entry 1 Singh Shawn · CIK 0001412071 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,028 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended, in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d). Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 21:15 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001415889-25-018200 · form4-06252025_050601.xml · derivative · entry 1 Singh Shawn · CIK 0001412071 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2035-06-23 F1 · derivative.exercise_date: Represents stock options (the "Options") granted pursuant to the Issuer's Amended and Restated 2019 Equity Omnibus Incentive Plan, as amended. The Options will begin vesting on June 23, 2025 (the "Grant Date"), and will vest in equal monthly installments over a three-year period until the Options become fully vested on the three (3) year anniversary of the Grant Date. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 22:06 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 4,854 | $2.96 | $14,358.13 |
DisclosureSEC source: 0001415889-24-019020 · form4-07022024_100738.xml · nonDerivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,487 F1 · shares: Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended. Read SEC document |
| June 24, 2024 Filed Jun 27, 2024 01:31 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001415889-24-018279 · form4-06272024_010639.xml · derivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2034-06-24 F1 · derivative.exercise_date: Represents stock options (the "Options") granted pursuant to the Issuer's Amended and Restated 2019 Equity Omnibus Incentive Plan, as amended. The Options will begin vesting on June 24, 2024 (the "Vesting Start Date"), and will vest in equal monthly installments over a three-year period until the Options become fully vested on the three (3) year anniversary of the Vesting Start Date. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 22:17 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 167 | $1.72 | $286.74 |
DisclosureSEC source: 0001415889-24-000344 · form4-01032024_100142.xml · nonDerivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,633 F1 · shares: Shares purchased pursuant to the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 20:05 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 167 | $1.59 | $265.45 |
DisclosureSEC source: 0001415889-23-010721 · form4-07052023_040705.xml · nonDerivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,466 F1 · shares: Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan ("ESPP"). Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 21:10 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 5,000 | $0.09 | $438.00 |
DisclosureSEC source: 0001415889-23-000041 · form4-01032023_090116.xml · nonDerivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,998 F1 · kind: Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan ("ESPP"). Read SEC document |
| August 17, 2022 Filed Aug 18, 2022 19:56 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | PurchaseCommon Stock | 600,000 | $0.17 | $103,200.00 |
DisclosureSEC source: 0001415889-22-008814 · form4-08182022_120836.xml · nonDerivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · By The 1997 Singh Family Trust U/R/D 05/29/97 Disclosed balance after: 626,234 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.1600 to $0.1975, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 30, 2022 Filed Jul 15, 2022 20:30 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 5,000 | $0.75 | $3,740.00 |
DisclosureSEC source: 0001415889-22-007688 · form4-07152022_040717.xml · nonDerivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,998 F1 · kind: Shares purchased under the VistaGen Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c) Read SEC document |
| May 12, 2022 Filed May 16, 2022 17:39 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001415889-22-004988 · form4-05162022_100519.xml · derivative · entry 3 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 100,000 shares Expires 2029-09-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Stock option vested 25% on the grant date of September 5, 2019, with the remainder vesting monthly over the 36 months thereafter. Read SEC document |
| May 12, 2022 Filed May 16, 2022 17:39 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | Exercise / conversionCommon Stock | 100,000 | $1.00 | $100,000.00 |
DisclosureSEC source: 0001415889-22-004988 · form4-05162022_100519.xml · nonDerivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:14 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001415889-22-002294 · form4-03032022_010311.xml · derivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-03-01 F1 · derivative.exercise_date: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan. Twenty-five percent (25%) of the total number of shares vest immediately on March 1, 2022 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 21:17 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 3,623 | $1.66 | $6,005.12 |
DisclosureSEC source: 0001415889-22-000034 · form4-01032022_010137.xml · nonDerivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,998 F1 · shares: Shares purchased under the VistaGen Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c) Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:10 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 5,000 | $1.95 | $9,732.50 |
DisclosureSEC source: 0001415889-21-003387 · form4-07022021_040701.xml · nonDerivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,375 F1 · shares: Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan on June 30, 2021 in a transaction exempt under Rule 16b-3(c). Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 20:13 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-21-002139 · form4-04272021_010440.xml · derivative · entry 3 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 20:13 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | Exercise / conversionCommon Stock | 5,000 | $1.50 | $7,500.00 |
DisclosureSEC source: 0001415889-21-002139 · form4-04272021_010440.xml · nonDerivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 21:58 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 5,000 | $0.45 | $2,260.50 |
DisclosureSEC source: 0001415889-21-000020 · form4-01042021_010131.xml · nonDerivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,375 F1 · shares: Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan on December 31, 2020 in a transaction exempt under Rule 16b-3(c). Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 21:58 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001415889-21-000020 · form4-01042021_010131.xml · derivative · entry 3 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-12-30 F2 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on December 31, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 21:20 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 5,000 | $0.45 | $2,240.00 |
DisclosureSEC source: 0001415889-20-001764 · form4-07012020_020757.xml · nonDerivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,375 F1 · shares: Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan ("ESPP") on June 30, 2020. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 21:10 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001415889-20-001064 · form4-04272020_050423.xml · derivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-04-23 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on April 23, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| October 21, 2019 Filed Oct 22, 2019 21:01 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001415889-19-001211 · form4-10222019_051000.xml · derivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2029-10-21 F1 · derivative.exercise_date: 25% of the Shares subject to the Option shall vest on date of grant October 21, 2019, and 1/24th of the remaining Shares subject to the Option shall vest on each monthly anniversary of the grant date thereafter. Read SEC document |
| May 28, 2019 Filed May 28, 2019 20:07 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 170,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000581 · form4-05282019_010542.xml · derivative · entry 2 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2029-05-28 F2 · derivative.exercise_date: Option granted under the Issuer's 2019 Omnibus Equity Incentive Plan (the "2019 Plan"), which was approved by the Issuer's Board of Directors on May 27, 2019, subject to the approval of the 2019 Plan by the Issuer's stockholders. The Option will not begin vesting until the 2019 Plan is approved by the Issuer's stockholders, at which time 25% of the Option will vest and the remainder will vest ratably in monthly installments over the following 36 months. In no event will the Option be exercisable prior to approval of the 2019 Plan by the Issuer's stockholders. Read SEC document |
| May 23, 2019 Filed May 28, 2019 20:07 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000581 · form4-05282019_010542.xml · derivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2029-05-23 F1 · derivative.exercise_date: Option granted under the Issuer's Amended and Restated 2016 Stock Incentive Plan, as amended. 50,000 of the shares subject to the Option will vest on the Vesting Start Date of May 23, 2019, and 1/36th of the remaining shares subject to the Option will vest on each monthly anniversary of the Vesting Start Date thereafter. Read SEC document |
| January 14, 2019 Filed Jan 15, 2019 02:55 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 220,000 | $1.70 Strike: $1.70 | $374,000.00 |
DisclosureSEC source: 0001415889-19-000052 · form4-01142019_090108.xml · derivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2029-01-14 F1 · derivative.exercise_date: 25% of the shares subject to the Option reported herein shall vest on the Vesting Start Date of January 14, 2019, and 1/24th of the remaining shares subject to the Option shall vest on each monthly anniversary of the Vesting Start Date thereafter. Read SEC document |
| January 14, 2019 Filed Jan 15, 2019 21:29 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-19-000055 · form4-01152019_010122.xml · derivative · entry 7 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2019-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 14, 2019 Filed Jan 15, 2019 21:29 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,125 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-19-000055 · form4-01152019_010122.xml · derivative · entry 6 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,125 shares Expires 2019-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 14, 2019 Filed Jan 15, 2019 21:29 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | Exercise / conversionStock Option (Right to Buy) · Derivative | 21,250 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-19-000055 · form4-01152019_010122.xml · derivative · entry 5 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,250 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 14, 2019 Filed Jan 15, 2019 21:29 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | Exercise / conversionCommon Stock | 3,000 | $1.50 | $4,500.00 |
DisclosureSEC source: 0001415889-19-000055 · form4-01152019_010122.xml · nonDerivative · entry 3 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 14, 2019 Filed Jan 15, 2019 21:29 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | Exercise / conversionCommon Stock | 1,125 | $1.50 | $1,687.50 |
DisclosureSEC source: 0001415889-19-000055 · form4-01152019_010122.xml · nonDerivative · entry 2 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 14, 2019 Filed Jan 15, 2019 21:29 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | Exercise / conversionCommon Stock | 21,250 | $1.50 | $31,875.00 |
DisclosureSEC source: 0001415889-19-000055 · form4-01152019_010122.xml · nonDerivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:28 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-18-001322 · form4-08312018_020839.xml · derivative · entry 16 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2027-04-26 F11 · derivative.exercise_date: The option vests monthly over a period of three years commencing 4/26/2017. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:28 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | Disposition to issuerStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001415889-18-001322 · form4-08312018_020839.xml · derivative · entry 15 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 175,000 shares Expires 2027-04-26 F10 · shares: The reporting person agreed to cancellation of an option granted to him on 4/26/2017 in exchange for a new option having a lower exercise price. F11 · derivative.exercise_date: The option vests monthly over a period of three years commencing 4/26/2017. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:28 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-18-001322 · form4-08312018_020839.xml · derivative · entry 14 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2026-11-09 F9 · derivative.exercise_date: The option vests monthly over a period of three years commencing 11/9/2016. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:28 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001415889-18-001322 · form4-08312018_020839.xml · derivative · entry 13 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2026-11-09 F8 · shares: The reporting person agreed to cancellation of an option granted to him on 11/9/2016 in exchange for a new option having a lower exercise price. F9 · derivative.exercise_date: The option vests monthly over a period of three years commencing 11/9/2016. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:28 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-18-001322 · form4-08312018_020839.xml · derivative · entry 12 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2026-06-19 F7 · derivative.exercise_date: The option vests monthly over a period of four years commencing 6/19/2016. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:28 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | Disposition to issuerStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001415889-18-001322 · form4-08312018_020839.xml · derivative · entry 11 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2026-06-19 F6 · shares: The reporting person agreed to cancellation of an option granted to him on 6/19/2016 in exchange for a new option having a lower exercise price. F7 · derivative.exercise_date: The option vests monthly over a period of four years commencing 6/19/2016. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:28 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-18-001322 · form4-08312018_020839.xml · derivative · entry 10 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2021-04-26 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:28 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001415889-18-001322 · form4-08312018_020839.xml · derivative · entry 9 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-04-26 F5 · shares: The reporting person agreed to cancellation of an option granted to him on 4/26/2011 in exchange for a new option having a lower exercise price. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:28 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 21,250 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-18-001322 · form4-08312018_020839.xml · derivative · entry 8 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 Underlying: Common Stock · 21,250 shares Expires 2019-12-30 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:28 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | Disposition to issuerStock Option (Right to Buy) · Derivative | 21,250 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001415889-18-001322 · form4-08312018_020839.xml · derivative · entry 7 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,250 shares Expires 2019-12-30 F4 · shares: The reporting person agreed to cancellation of an option granted to him on 12/30/2009 in exchange for a new option having a lower exercise price. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:28 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-18-001322 · form4-08312018_020839.xml · derivative · entry 6 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2019-11-04 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:28 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001415889-18-001322 · form4-08312018_020839.xml · derivative · entry 5 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2019-11-04 F3 · shares: The reporting person agreed to cancellation of an option granted to him on 11/4/2009 in exchange for a new option having a lower exercise price. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:28 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 1,125 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-18-001322 · form4-08312018_020839.xml · derivative · entry 4 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,125 Underlying: Common Stock · 1,125 shares Expires 2019-06-17 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:28 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,125 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001415889-18-001322 · form4-08312018_020839.xml · derivative · entry 3 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,125 shares Expires 2019-06-17 F2 · shares: The reporting person agreed to cancellation of an option granted to him on 6/17/2009 in exchange for a new option having a lower exercise price. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:28 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-18-001322 · form4-08312018_020839.xml · derivative · entry 2 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2019-03-24 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:28 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001415889-18-001322 · form4-08312018_020839.xml · derivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2019-03-24 F1 · shares: The reporting person agreed to cancellation of an option granted to him on 3/24/2009 in exchange for a new option having a lower exercise price. Read SEC document |
| February 02, 2018 Filed Feb 5, 2018 21:55 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001415889-18-000187 · form4-02052018_010209.xml · derivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-02-02 F1 · derivative.exercise_date: 25% of the Shares subject to the Option shall vest on date of grant February 2, 2018, and 1/24th of the remaining Shares subject to the Option shall vest on each monthly anniversary of the grant date thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.